Publications & Presentations

Mar 1, 2024

Facioscapulohumeral Muscular Dystrophy European Patient Survey: Assessing Patient Reported Disease Burden and Preferences in Clinical Trial Participation

Megan M McNiff, Sheila Hawkins, Bine Haase, Joanne Bullivant, Tammy McIver, Olga Mitelman, Nicholas Emery, Giorgio Tasca, Nicol Voermans, Jordi Diaz-Manera

Dec 11, 2023

Single-cell transcriptome analyses further elucidate the mechanism of action of EED inhibition on HbF induction

Summer Xia Han, Emily Fitz, Allysa Allen, Avik Choudhuri, Caroline V. Sartain, Paul A. Bruno, Jeffrey W. Jacobs, Billy Stuart

Oct 3, 2023

Safety and Tolerability Data with Losmapimod in FSHD

M-H Jouvin, V Ramana, J Jiang

Oct 3, 2023

A Systematic Literature Review to Assess the Level of Evidence in Facioscapulohumeral Muscular Dystrophy

L Barnieh, R Beckerman, H Emich, K Eichinger, A Eldar-Lissai

Jun 15, 2023

Development of the HealthMeasures Facioscapulohumeral Muscular Dystrophy-32 (HM FSHD-32) Patient-Reported Outcome Measure

Shaunfield S, K Kaiser, CN Hurt, GJ Greene, D Peipert, A Eldar-Lissai, D Cella

May 7, 2023

APPLYING MACHINE LEARNING (ML) TO ESTIMATE THE PREVALENCE OF FACIOSCAPULOHUMERAL MUSCULAR DYSTROPHY (FSHD) AND RELATED DISEASE BURDEN; FINDINGS FROM UNITED STATES CLAIMS ANALYSIS

Winnen A, S Srivatsa, A Eldar‐Lissai, I Kouchlev, G Jones, T Zuroske

Apr 22, 2023

Design of REACH: Phase 3 Randomized, Double-Blind, Placebo-Controlled, 48-Week Study of the Efficacy and Safety of Losmapimod in FSHD

Tawil R, J Han, L Wang, J Vissing, J Statland, J Jiang

Apr 22, 2023

Muscle Ultrasound in an Open-Label Study of Losmapimod in Subjects with FSHD1

Kools J, N Voermans, K Mul, J Jiang, M Karlsson

Mar 19, 2023

Results from 96 Weeks of Dosing from the Open-Label Extension of a Phase 2 Trial of Losmapimod in Subjects with FSHD: ReDUX4

Wang L, J Han, J Jiang, R Tawil

Oct 11, 2022

Measuring Progression in FSHD: Implications for Clinical Trials

Shoskes J, L Wang, S Sacconi